CCR1 Antagonist Rheumatoid Arthritis Trial 2 (CARAT-2), a phase II double-blind, randomized, placebo-controlled clinical trial, found that CCX354-C is effective and tolerated in 160 patients with RA.[63] Based on the CARAT-2 results, it is encouraging and promising that CCR1 antagonist might be a potential therapeutic target for CAVD treatment, which should be further studied and solved. Here, CCR1 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.